The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.
Brian M. Wolpin
No relevant relationships to disclose
Kimmie Ng
No relevant relationships to disclose
Andrew X. Zhu
No relevant relationships to disclose
Thomas Adam Abrams
No relevant relationships to disclose
Peter C. Enzinger
No relevant relationships to disclose
Nadine McCleary
No relevant relationships to disclose
Jeffrey A. Meyerhardt
No relevant relationships to disclose
Deborah Schrag
No relevant relationships to disclose
Eunice Lee Kwak
No relevant relationships to disclose
Jill N. Allen
No relevant relationships to disclose
Pankaj Bhargava
Stock Ownership - AVEO
Other Remuneration - AVEO
Jennifer A. Chan
No relevant relationships to disclose
Wolfram Goessling
No relevant relationships to disclose
Lawrence Scott Blaszkowsky
No relevant relationships to disclose
Meaghan Elliott
No relevant relationships to disclose
Maria Shellock
No relevant relationships to disclose
Eileen Regan
No relevant relationships to disclose
Charles S. Fuchs
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Mersana; Pfizer; Roche/Genentech; Sanofi